2020 ESMO临床实践指南:青春期后癌症患者生育能力保留和治疗后妊娠

2020-09-16 欧洲肿瘤内科学会 Ann Oncol . 2020 Sep 16;

2020年9月,欧洲肿瘤内科学会(ESMO)发布了青春期后癌症患者生育能力保留和治疗后妊娠指南。癌症仍是全世界范围内的工作健康问题,也包括年轻成人。在癌症确诊时,有相当大比例的年轻患者会担忧抗癌治疗对

中文标题:

2020 ESMO临床实践指南:青春期后癌症患者生育能力保留和治疗后妊娠

英文标题:

Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines

发布机构:

欧洲肿瘤内科学会

发布日期:

2020-09-16

简要介绍:

2020年9月,欧洲肿瘤内科学会(ESMO)发布了青春期后癌症患者生育能力保留和治疗后妊娠指南。癌症仍是全世界范围内的工作健康问题,也包括年轻成人。在癌症确诊时,有相当大比例的年轻患者会担忧抗癌治疗对生育能力的影响以及未来的生育机会。本文主要针对青春期后癌症患者生育能力保留以及后期治疗后妊娠的相关内容提供指导建议。

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=2020 ESMO临床实践指南:青春期后癌症患者生育能力保留和治疗后妊娠.pdf)] GetToolGuiderByIdResponse(projectId=1, id=0b54a1c0019901e9, title=2020 ESMO临床实践指南:青春期后癌症患者生育能力保留和治疗后妊娠, enTitle=Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines, guiderFrom=Ann Oncol . 2020 Sep 16;, authorId=0, author=, summary=2020年9月,欧洲肿瘤内科学会(ESMO)发布了青春期后癌症患者生育能力保留和治疗后妊娠指南。癌症仍是全世界范围内的工作健康问题,也包括年轻成人。在癌症确诊时,有相当大比例的年轻患者会担忧抗癌治疗对, cover=https://img.medsci.cn/20201014/1602609533349_2020535.jpg, journalId=0, articlesId=null, associationId=14, associationName=欧洲肿瘤内科学会, associationIntro=欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology )是1975年成立的非盈利组织,是欧洲领先的专业组织,致力于提高肿瘤内科的专业性,推进癌症治疗和护理的多学科诊疗方法。, copyright=0, guiderPublishedTime=Wed Sep 16 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2020年9月,欧洲肿瘤内科学会(ESMO)发布了青春期后癌症患者生育能力保留和治疗后妊娠指南。癌症仍是全世界范围内的工作健康问题,也包括年轻成人。在癌症确诊时,有相当大比例的年轻患者会担忧抗癌治疗对生育能力的影响以及未来的生育机会。本文主要针对青春期后癌症患者生育能力保留以及后期治疗后妊娠的相关内容提供指导建议。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=2813, tagName=癌症患者)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=2813, guiderKeyword=癌症患者, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=1610, appHits=74, showAppHits=0, pcHits=313, showPcHits=1536, likes=1, shares=4, comments=8, approvalStatus=1, publishedTime=Wed Oct 14 01:20:55 CST 2020, publishedTimeString=2020-09-16, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Wed Oct 14 01:18:59 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Fri Jan 05 08:08:15 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 ESMO临床实践指南:青春期后癌症患者生育能力保留和治疗后妊娠.pdf)])
2020 ESMO临床实践指南:青春期后癌症患者生育能力保留和治疗后妊娠.pdf
下载请点击:
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=911732, encodeId=0138911e3264, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=50571687662, createdName=1de4d735m97(暂无匿称), createdTime=Mon Dec 28 21:23:17 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894908, encodeId=578689490847, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8505106550, createdName=李启刚, createdTime=Tue Oct 27 19:57:43 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894585, encodeId=f1b8894585b6, content=挺好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fa2381620, createdName=12314969m72暂无昵称, createdTime=Mon Oct 26 18:23:12 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891938, encodeId=992a891938b3, content=感谢分享,感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201014/111c45ea505f459c93d076fb930b9ec4/96fdce3d55574e24a078f71b9d8e58f3.jpg, createdBy=21f65395610, createdName=葡萄有你不酸了, createdTime=Wed Oct 14 08:36:30 CST 2020, time=2020-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891937, encodeId=f9d889193ef5, content=。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2155425702, createdName=ms8000000486612886, createdTime=Wed Oct 14 08:33:48 CST 2020, time=2020-10-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=911732, encodeId=0138911e3264, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=50571687662, createdName=1de4d735m97(暂无匿称), createdTime=Mon Dec 28 21:23:17 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894908, encodeId=578689490847, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8505106550, createdName=李启刚, createdTime=Tue Oct 27 19:57:43 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894585, encodeId=f1b8894585b6, content=挺好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fa2381620, createdName=12314969m72暂无昵称, createdTime=Mon Oct 26 18:23:12 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891938, encodeId=992a891938b3, content=感谢分享,感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201014/111c45ea505f459c93d076fb930b9ec4/96fdce3d55574e24a078f71b9d8e58f3.jpg, createdBy=21f65395610, createdName=葡萄有你不酸了, createdTime=Wed Oct 14 08:36:30 CST 2020, time=2020-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891937, encodeId=f9d889193ef5, content=。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2155425702, createdName=ms8000000486612886, createdTime=Wed Oct 14 08:33:48 CST 2020, time=2020-10-14, status=1, ipAttribution=)]
    2020-10-27 李启刚

    值得学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=911732, encodeId=0138911e3264, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=50571687662, createdName=1de4d735m97(暂无匿称), createdTime=Mon Dec 28 21:23:17 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894908, encodeId=578689490847, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8505106550, createdName=李启刚, createdTime=Tue Oct 27 19:57:43 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894585, encodeId=f1b8894585b6, content=挺好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fa2381620, createdName=12314969m72暂无昵称, createdTime=Mon Oct 26 18:23:12 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891938, encodeId=992a891938b3, content=感谢分享,感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201014/111c45ea505f459c93d076fb930b9ec4/96fdce3d55574e24a078f71b9d8e58f3.jpg, createdBy=21f65395610, createdName=葡萄有你不酸了, createdTime=Wed Oct 14 08:36:30 CST 2020, time=2020-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891937, encodeId=f9d889193ef5, content=。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2155425702, createdName=ms8000000486612886, createdTime=Wed Oct 14 08:33:48 CST 2020, time=2020-10-14, status=1, ipAttribution=)]
    2020-10-26 12314969m72暂无昵称

    挺好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=911732, encodeId=0138911e3264, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=50571687662, createdName=1de4d735m97(暂无匿称), createdTime=Mon Dec 28 21:23:17 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894908, encodeId=578689490847, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8505106550, createdName=李启刚, createdTime=Tue Oct 27 19:57:43 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894585, encodeId=f1b8894585b6, content=挺好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fa2381620, createdName=12314969m72暂无昵称, createdTime=Mon Oct 26 18:23:12 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891938, encodeId=992a891938b3, content=感谢分享,感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201014/111c45ea505f459c93d076fb930b9ec4/96fdce3d55574e24a078f71b9d8e58f3.jpg, createdBy=21f65395610, createdName=葡萄有你不酸了, createdTime=Wed Oct 14 08:36:30 CST 2020, time=2020-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891937, encodeId=f9d889193ef5, content=。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2155425702, createdName=ms8000000486612886, createdTime=Wed Oct 14 08:33:48 CST 2020, time=2020-10-14, status=1, ipAttribution=)]
    2020-10-14 葡萄有你不酸了

    感谢分享,感谢

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=911732, encodeId=0138911e3264, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=50571687662, createdName=1de4d735m97(暂无匿称), createdTime=Mon Dec 28 21:23:17 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894908, encodeId=578689490847, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8505106550, createdName=李启刚, createdTime=Tue Oct 27 19:57:43 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894585, encodeId=f1b8894585b6, content=挺好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fa2381620, createdName=12314969m72暂无昵称, createdTime=Mon Oct 26 18:23:12 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891938, encodeId=992a891938b3, content=感谢分享,感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201014/111c45ea505f459c93d076fb930b9ec4/96fdce3d55574e24a078f71b9d8e58f3.jpg, createdBy=21f65395610, createdName=葡萄有你不酸了, createdTime=Wed Oct 14 08:36:30 CST 2020, time=2020-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891937, encodeId=f9d889193ef5, content=。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2155425702, createdName=ms8000000486612886, createdTime=Wed Oct 14 08:33:48 CST 2020, time=2020-10-14, status=1, ipAttribution=)]
    2020-10-14 ms8000000486612886

    0

拓展阅读

2016 CCO临床实践指南:癌症患者抑郁的管理

加拿大安大略癌症治疗中心(CCO,Cancer Care Ontario) · 2016-07-15

2013 国际临床实践指南:癌症患者中心静脉导管血栓形成的治疗和预防

国际血栓形成和癌症创议(ITAC-CME,International Initiative on Thrombosis and Cancer) · 2013-01-01

2018 临床实践指南:青春期后女性癌症患者生育能力保留

国外肿瘤科相关专家小组(统称) · 2018-01-08

2018 ESMO临床实践指南:癌症患者贫血和铁缺乏的管理

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2018-02-20

2018 JSCO临床实践指南:儿童,青少年以及青年癌症患者生育能力保留

日本临床肿瘤学会(JSCO,Japan Society of Clinical Oncology) · 2018-03-26